EMLA Cream in Hysteroscopy Practice

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the efficacy of 5% lidocaine 25 mg-prilocaine 25 mg/g cream (EMLA®) applied to the uterine cervix for reducing pain during diagnostic hysteroscopy, using a visual analogue scale (VAS) for pain, and whether it can replace general anesthesia that may be required for some cases of office hysteroscopy.

Official Title
-----------------
Lidocaine-Prilocaine (EMLA®) Cream in Hysteroscopy Practice: A Prospective Randomized Non-blinded Controlled Study

Conditions
-----------------
Anesthetics, Local

Intervention / Treatment
-----------------
* Drug: EMLA
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients that must perform a diagnostic hysteroscopy. Acceptance to participate in the study. Signed informed consent. Not taking analgesics (acetaminophen, ibuprofen, mefenamic acid) 6h before admission. Absence of sedative use 24 h before admission Exclusion Criteria: Hypersensitivity or allergy to anesthetics refusal of the patient Patients under age 18 and pregnant. Patients on anti-arrhythmic drugs due to possibility of drug interaction. Unbearable pain that involves other analgesic measures. Allergic reactions to topical anesthetics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A (EMLA)<br>3 mL EMLA® cream 5% will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn. | Drug: EMLA<br> <br> |
| Placebo Comparator: Group B (Placebo)<br>3 mL of ultrasonic gel will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn. | Other: Placebo<br> <br> * Other names: Ultrasound gel;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain experienced during the procedure scored using a VAS. | All women will be asked to score the pain they experienced during the procedure using a VAS that consists of a 10-cm line scaled from 0 to 10 (0 = no pain and 10 = severe pain). Women will be asked to verbally specify the number that represented their level of perceived pain intensity during the hysteroscopy immediately after the procedure. After completing the hysteroscopy, women will be asked if they would recommend the procedure to other women, if they had wished to abandon the hysteroscopy, and whether they would repeat the procedure if needed. | Procedure |